Does Ozempic Affect Your Sleep?

Yes, GLP-1 drugs affect sleep, and the effect runs in two directions at once. Which one applies to you depends mostly on why you’re taking the drug and what was already wrong with your sleep before you started.

For the roughly 40% of American adults with obesity who also have obstructive sleep apnea, semaglutide and tirzepatide are, on the current evidence, unambiguously good for sleep. For a smaller group without apnea, the same drugs are producing a fairly consistent pattern of complaints: trouble falling asleep, waking in the night, unusually vivid or disturbing dreams. Both things are true simultaneously. The confusion in most consumer coverage comes from treating “GLP-1 drugs and sleep” as one question when it’s really two, with two different bodies of evidence behind them.

The apnea evidence is the strongest thing here

Start with what’s been through a proper randomized trial. The SURMOUNT-OSA study, led by pulmonologist Atul Malhotra at UC San Diego and published in the New England Journal of Medicine in 2024, put 469 adults with obesity and moderate-to-severe obstructive sleep apnea on tirzepatide or placebo for a year. The apnea-hypopnea index, the count of breathing interruptions per hour of sleep, dropped by roughly 27 to 30 events per hour in the tirzepatide group, against about 5 to 6 in the placebo group. Between 43% and 51.5% of participants on the highest dose no longer met the clinical criteria for sleep apnea by the end of the trial. Weight loss was clearly part of why (less tissue around the airway means fewer collapses), but the drug also improved patient-reported sleep quality by more than weight loss alone would predict.

That result was strong enough that the FDA approved tirzepatide, sold as Zepbound, for moderate-to-severe OSA in adults with obesity in December 2024, the first drug of its kind approved for that indication. If your sleep problem is loud snoring, witnessed pauses in breathing, and daytime exhaustion despite a full night in bed, this is the part of the GLP-1 story that’s actually settled.

The other side: what Reddit is saying that trials aren’t measuring yet

The complaints run the opposite direction, and they’re harder to pin down precisely because almost none of them come from a trial designed to measure sleep as a primary outcome. The best current window into them is a 2026 study out of the University of Pennsylvania, by Neil Sehgal, Jena Shaw Tronieri, Lyle Ungar, and Sharath Chandra Guntuku, published in the new Springer Nature journal Nature Health. The team used machine learning to sort through 410,198 Reddit posts and comments from 67,008 self-identified semaglutide and tirzepatide users, posted between 2019 and 2025. Gastrointestinal symptoms dominated, as expected: nausea in 36.9% of people who reported any side effect, fatigue in 16.7%, vomiting in 16.3%. Insomnia showed up too, not as a headline finding, but as a repeated, low-single-digits theme among tirzepatide users in particular, alongside vivid or unusual dreams, menstrual changes, and temperature swings, none of which appear prominently in the drugs’ official prescribing information.

That gap between trial data and Reddit data is the study’s actual point: clinical trials are built to catch the side effects investigators think to ask about, at the visit intervals investigators choose. A drug taken by tens of millions of people generates a much finer-grained, much noisier signal than any trial arm, and sleep disturbance is exactly the kind of complaint (subjective, variable, easy to attribute to something else) that tends to fall through that gap until enough people say it in the same place.

None of this means the underlying cause is understood. GLP-1 receptors sit in the hypothalamus and brainstem, regions that also regulate REM sleep and arousal, so a direct neurological pathway is plausible. So is an indirect one: delayed gastric emptying can leave food sitting uncomfortably in the stomach at bedtime, and swings in blood glucose overnight can fragment sleep on their own, independent of anything happening in the brain. Right now this is a live research question, not a settled one, and anyone quoting you a precise percentage of users who get vivid dreams is quoting a number nobody has actually measured in a controlled way.

The same person can experience both effects, on different timelines

The apnea finding and the insomnia complaints aren’t necessarily describing different populations. They can describe the same person at different points on the same prescription. Weight loss on tirzepatide or semaglutide accumulates gradually, typically over 6 to 18 months, and the SURMOUNT-OSA improvements in breathing were measured at the 52-week mark, after substantial weight had already come off. The nausea, dose-increase discomfort, and disrupted nights that show up in the Reddit data cluster earliest and hardest around the dose-escalation steps that happen every four weeks in the first few months of treatment, before most of the airway benefit has had time to accrue. It’s entirely possible for someone with obesity and undiagnosed apnea to have a markedly worse month of sleep in month two of treatment and a genuinely better year of sleep by month twelve, and for both of those to be honestly reported as “how this drug affected my sleep” depending on when you asked.

That timeline gap is also why a single-percentage answer to “does this drug disrupt sleep” is close to useless. Someone titrating up on tirzepatide in week six, without apnea, with a still-adjusting gut, is in the population most likely to notice new nighttime waking or an unusually vivid dream. Someone eight months into treatment who started with a severe apnea diagnosis is more likely to notice the opposite: fewer awakenings, less daytime fatigue, a partner who’s stopped complaining about snoring. Both are “on a GLP-1 drug.” Neither report is wrong. They’re just describing different windows of the same treatment.

Mornings are where the appetite-timing shift shows up

The part of this story that’s actually about mornings is less about how you sleep and more about what happens the moment you wake up. GLP-1 drugs slow gastric emptying and blunt hunger signaling for hours after each dose, and by patient account that suppression tends to be strongest in the morning, enough that skipping breakfast, or eating much later than usual, becomes a routine adjustment rather than an occasional one. That’s a pattern documented in patient self-report rather than a dedicated clinical trial, so it deserves the same caution as the dream reports above: real and repeated, but not yet quantified the way the SURMOUNT-OSA apnea numbers are.

It also compounds with whatever else is already shaping how a given morning feels. Sleep inertia, the grogginess in the first stretch after waking, has more to do with which sleep stage the alarm interrupts than with anything a GLP-1 drug does directly, a distinction explored in more depth in an investigation into why grogginess varies so much day to day. Someone on tirzepatide who wakes up nauseated, skips breakfast, and reaches for a second cup of coffee to compensate is layering several separate effects on top of each other; it helps to know how long that coffee is actually still active in the body before assuming the fog has one cause. And for the subset of users cycling melatonin or other over-the-counter aids to manage new-onset insomnia, the honest answer is that few of those have trial evidence behind them, one more variable to weigh before adding it to an already-shifting routine.

What this has to do with an alarm app

DontSnooze doesn’t touch any of this, and it would be dishonest to pretend otherwise. If a GLP-1 drug is keeping you up at 2 a.m. with nausea or an unusually vivid dream, no app is going to fix that; that’s a conversation with the prescriber, possibly about dose pace rather than the drug itself. What an accountability alarm can do is narrower: it addresses the moment where you’re capable of getting up but don’t, which is a behavioral problem, not a pharmacological one. For someone whose sleep is fragmented by a new medication and who then also has trouble hauling themselves out of bed once morning actually arrives, that second piece is the only piece DontSnooze was ever built to help with. It’s a narrow fix for a narrow slice of a much bigger problem, and knowing that in advance is more useful than finding it out after the app doesn’t touch the part that’s actually keeping you up.